Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (321 to 35° weeks of gestation);Recomendaciones de uso de palivizumab para la prevención de la infección por virus respiratorio sincitial en prematuros de 32 1 a35° semanas de gestación

Anales de Pediatria

Volumn 73, Issue 2, 2010, Pages

  Figueras Aloy, J ^a   Carbonell Estrany, X ^a  

^a Fetal I+D Fetal Medicine Research Center   (Spain)

Author keywords

Bronchiolitis; Hospitalization; Late premature; Monoclonal antibodies; Palivizumab; RSV

Indexed keywords

PALIVIZUMAB;

CIGARETTE SMOKING; GESTATIONAL AGE; GROUPS BY AGE; HUMAN; INFECTION PREVENTION; MATERNAL BEHAVIOR; PREGNANCY; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK FACTOR; SPAIN; TREATMENT INDICATION;

EID: 77955232117     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2010.05.026     Document Type: Article

References (35)

1. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-7.
2. Carbonell-Estrany X, Quero Jimenez J; Comité de Estandares de la SEN. Recomendaciones para la prevencion de la infeccién por virus respiratorio sincitial. An Esp Pediatr. 2000;52:372-4.
3. Carbonell-Estrany X, Quero Jimenez J; Comité de Esténdares de la SEN. Recomendaciones para la prevencioén de la infeccioén por virus respiratorio sincitial: Revisién. An Esp Pediatr. 2002;56: 334-6.
4. Figueras J, Quero J; y Comisién de Esténdares de la Sociedad Espanola de Neonatologia. Recomendaciones para la prevencion de la infeccién por virus respiratorio sincitial. An Pediatr (Barc). 2005;63:357-62.
5. Meissner HC, Long SS; American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections. Pediatrics. 2003;112:1447-52.
6. Stein RT, Sherill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354: 541-5.
7. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe Respiratory Syncytial Virus Bronchiolitis in Infancy and Asthma and Allergy at Age 13. Am J Respir Crit Care Med. 2005;171:137-41.
8. Sigurs N, Bjarnasson R, Sigurbergsson F, Kjellman B. Respiratory Syncytial Virus Bronchiolitis in Infancy is an Important Risk Factor for Asthma and Allergy at Age 7. Am J Respir Crit Care Med. 2000;161:1501-7.
9. Piedimonte G. The association between respiratory syncytial virus infection and reactive airway disease. Respir Med. 2002;96(suppl B):S25-S9.
10. Martinez FD. Respiratory Syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J. 2003;22:S76-82.
11. Mejias A, Chavez-Bueno S, Rios AM, Saavedra-Lozano J, Fonseca Aten M, Hatfield J, et al. Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decrease Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model. Antimicrob Agents Chemother. 2004;48: 1811 -1822.
12. Mejias A, Chavez-Bueno S, Rios AM, Fonseca-Aten M, Gomez AM, Jafri HS, et al. Asma y virus respiratorio sincitial. Nuevas oportunidades de intervencion terapéutica. An Pediatr (Barc). 2004;61:252-60.
13. Mejias A, Ramilo O. Asma y virus respiratorio sincitial ¿Mito o realidad?An Esp Pediatr 2002;57:199-204.
14. Simoes EAF, Groothuis JR, Carbonell-Estrany X, Rieger CHL, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, Respiratory Syncytial Virus and subsequent recurrent wheezing. J Pediatr. 2007;151:34-42.
15. Roeckl-Wedmann I, Liese JG, Grill E. Economic evaluation of possible prevention of RSV-related hospitalisations in premature infants in Germany. Eur J Pediatr. 2003;162:237-44.
16. Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, et al. Cost-effectiveness of palivizumab in New Zealand. J Pediatr Child Health. 2002;38:352-7.
17. Laézaro P, Figueras J, Domenech E, Echaniz I, Closa R, Wood MA, et al. La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infeccion por VRS en prematuros de 32-35 semanas en Espana. An Pediatr (Barc). 2006;65:316-24.
18. Léazaro P, Figueras J, Domenech E, Closa R, Echaniz I, Wood MA, et al. Coste-efectividad del palivizumab para prevenir el VRS en prematuros y ninos con enfermedad pulmonar crénica en Espana. Pharmacoeconomics Span Res Art. 2007;4:59-70.
19. Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis. 2008;27:891-9.
20. Redatto dal Consiglio Direttivo della Societéa Italiana di Neonatologéia. Raccomandazioni della Societaé Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Aggiornamento 2004. Acta Neonatologica. 2004;1:1-11.
21. CDC. Brief report: Respiratory Syncytial Virus activity. United States, 2005-2006. MMWR. 2006;55:1277-9.
22. Horn SD, Smout RJ. Effect of Prematurity on Respiratory Syncytial Virus Hospital Resource Use and Outcomes. J Pediatr. 2003;143:S133-S41.
23. Sampalis JS. Morbidity and Mortality after RSV-Associated Hospitalizations Among Premature Canadian Infants. J Pediatr. 2003;143:S150-6.
24. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, et al. Direct Cost Analyses of palivizumab Treatment in a Cohort of At-Risk Children: Evidence From the North Carolina Medicaid Program. Pediatrics. 2004;114:1612-9.
25. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143:S118-26.
26. Bradley JP, Bacharier LB, Bonfiglio JA, Schechtman KB, Strunk R, Storch G, et al. Severity of Respiratory Syncytial Virus Bronchiolitis Is Affected by Cigarrete Smoke Exposure and Atopy. Pediatrics. 2005;115:e7-14.
27. Welliver RC. Review of Epidemiology and Clinical Risk Factors for Severe Respiratory Syncytial Virus Infection. J Pediatr. 2003;143:S112-7.
28. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The Burden of Respiratory Syncytial Virus infection in young children. N Engl J Med. 2009;360:588-98.
29. Figueras-Aloy J, Carbonell-Estrany X, Quero J; for the IRIS Study Group. Case-Control Study of the Risk Factors Linked to Respiratory Syncytial Virus Infection Requiring Hospitalization in Premature Infants Born at a Gestational Age of 33-35 Weeks in Spain. Pediatr Infect Dis J. 2004;23:815-20.
30. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmén-Cabanas J, Echaniz-Urcelay I, et al. FLIP-2 Study: Risk Factors Linked to Respiratory Syncytial Virus Infection Requiring Hospitalization in Premature Infants Born in Spain at a Gestational Age of 32 to 35 Weeks. Pediatr Infect Dis J. 2008;27:788-93.
31. 0 semanas de gestacioén en Espana. An Pediatr (Barc). 2009;71:47-53.
32. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimeénez J, Fernéan-dez-Colomer B, Guzman-Cabanas J, Echaniz-Urcelay I, et al. Efectividad del palivizumab en la prevencioén de la infeccioén por virus respiratorio sincitial en prematuros de 32.1 a 35.0 semanas de gestacion en Espana. Acta Pediatr Esp. 2010;68:13-8.
33. Committee on Infectious Diseases. American Academy of Pediatrics. Policy Statement - Modified Recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics online Sept 7, 2009; doi:10.1542/peds. p. 2009-2345.
34. Simoes EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res. 2008;9:78.
35. Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin. 2009:1585-91.